Eledon Pharmaceuticals, Inc.
ELDN
$2.82
-$0.11-3.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 16.72M | 16.54M | 16.98M | 19.76M | 19.65M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 84.60M | 86.47M | 83.25M | 86.46M | 87.90M |
| Operating Income | -84.60M | -86.47M | -83.25M | -86.46M | -87.90M |
| Income Before Tax | -98.53M | -78.11M | -45.58M | -79.36M | 15.07M |
| Income Tax Expenses | 35.00K | 35.00K | 35.00K | 431.00K | 431.00K |
| Earnings from Continuing Operations | -98.56 | -78.15 | -45.62 | -79.79 | 14.64 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -98.56M | -78.15M | -45.62M | -79.79M | 14.64M |
| EBIT | -84.60M | -86.47M | -83.25M | -86.46M | -87.90M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -0.96 | -0.83 | -0.56 | -1.13 | 1.00 |
| Normalized Basic EPS | -0.60 | -0.52 | -0.35 | -0.68 | 0.39 |
| EPS Diluted | -0.96 | -0.83 | -0.56 | -1.13 | -1.19 |
| Normalized Diluted EPS | -0.60 | -0.52 | -0.35 | -0.68 | 0.33 |
| Average Basic Shares Outstanding | 399.56M | 363.10M | 327.80M | 301.74M | 276.53M |
| Average Diluted Shares Outstanding | 399.56M | 363.10M | 327.80M | 301.74M | 280.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |